• A five foot tall white robot in a hospital hallway

    UTMB Deploys Robots to Support Hospital Staff

    The University of Texas Medical Branch welcomed some new staff members at the Angleton Danbury campus this week: two nearly life-sized robots programmed to support the human staff and free up nurses from certain tasks to allow them more time to spend with patients.

  • UTMB Awarded Project Agreement Up to $24.7M from the U.S. Department of Defense to Develop mRNA Vaccines to Prevent Biological Threat Agent Diseases

    UTMB has been awarded an agreement up to nearly $25 million from the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) (within the Administration for Strategic Preparedness and Response (ASPR)), for their efforts in the collaborative development of vaccines to protect against infection by Ebola (EBOV), Sudan (SUDV), Marburg (MARV), and Lassa (LASV) viruses. This project award was executed via Other Transaction Authority (OTA) to UTMB through the Medical CBRN Defense Consortium (MCDC).

  • UTMB research links COVID-19 pandemic to poor mental health in adolescents

    A new University of Texas Medical Branch study links COVID-19 restrictions to poor mental health in adolescents. “While it was necessary to prevent the pre-vaccine spread of COVID-19, removing children from school was not without consequences,” said Dr. Jeff Temple, Vice Dean for research at UTMB’s School of Nursing and the director of the Center for Violence Prevention. Temple is the lead author of the study published in the Journal of Adolescent Health.

  • An image of a pill capsule full of gears

    UTMB drug discovery partnership awarded $56 million grant

    Thanks to a $56 million grant, the University of Texas Medical Branch and global health care company Novartis will enhance their work together to discover drugs to fight off the next pandemic. The grant comes from the National Institute of Allergy and Infectious Diseases (NIAID) and is one of nine such grants awarded by NIAID to establish Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.